EMA, risks stem not regular therapy

Risks to the health of the patients (ANSA) – ROMA, 22 APR – may arise from the use non-regulated stem cell-based therapies. It means that it is the European Agency of medicines EMA. “Allows the producers to avoid compliance with quality standards, for example through inadequate reclassifications of treatments – underlines the EMA – could expose patients to cross-contamination,” and this translates into “the risks for individual patients, short – and long-term. “(ANSA). All rights reserved